S'abonner

Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial - 22/09/21

Doi : 10.1016/j.jpeds.2021.05.051 
Christine M. Pierce, MD 1, , Min H. Zhang, PhD 2, Baldvin Jonsson, MD, PhD 3, Dinu Iorga, MD 4, Narayan Cheruvu, PhD 4, Cecile C. Balagtas, PhD 5, Robin H. Steinhorn, MD 6
1 Pediatric and Neonatal Intensive Care, Great Ormond Street Hospital for Children, London, United Kingdom 
2 Global Biometrics and Data Management, Pfizer Inc, La Jolla, CA 
3 Department of Neonatology, Karolinska Institute and University Hospital, Stockholm, Sweden 
4 Pfizer Inc, Collegeville, PA 
5 Pfizer Inc, New York, NY 
6 Rady Children's Hospital and University of California San Diego, San Diego, CA 

Reprint requests: Dr Christine M. Pierce, Paediatric and Neonatal Intensive Care Unit, Great Ormond Street Hospital NHS Trust, Paediatric Intensive Care, Great Ormond St, London WC1N 3JH, United KingdomPaediatric and Neonatal Intensive Care UnitGreat Ormond Street Hospital NHS TrustPaediatric Intensive CareGreat Ormond StLondonWC1N 3JHUnited Kingdom

Abstract

Objective

To investigate the efficacy and safety of sildenafil added to inhaled nitric oxide (iNO) for newborn infants with persistent pulmonary hypertension of newborn (PPHN) or hypoxic respiratory failure (HRF) at risk of PPHN.

Study design

Part A of a multinational, randomized, double-blind, placebo-controlled trial. Infants ≤96 hours’ old, >34 weeks of gestation, receiving iNO (10-20 ppm on ≥50% FiO2) for PPHN or HRF at risk of PPHN, and oxygen index >15 to <60, were randomized (1:1) to intravenous (IV) sildenafil (loading: 0.1 mg/kg, over 30 minutes; maintenance: 0.03 mg/kg/h) or placebo, for up to 14 days. Coprimary end points were treatment failure rate (day 14/discharge) and time on iNO without treatment failure. Secondary end points included time on ventilation and oxygenation measures.

Results

Of 87 infants screened, 29 were randomized to IV sildenafil and 30 to placebo; 13 discontinued treatment (sildenafil, n = 6; placebo: n = 7), including 3 deaths (sildenafil: n = 2; placebo: n = 1). Treatment failure rates did not differ with sildenafil (27.6%) vs placebo (20.0%; P = .4935). Mean time on iNO was not different with sildenafil (4.1 days) vs placebo (4.1 days; P = .9850). No differences were noted in secondary end points. Most common adverse events (AEs) with sildenafil (≥10% infants) were hypotension (n = 8/29), hypokalemia (n = 7/29), anemia, drug withdrawal syndrome (n = 4/29, each), and bradycardia (n = 3/29). One serious AE (hypotension) was considered treatment-related.

Conclusions

IV sildenafil added to iNO was not superior to placebo in infants with PPHN or HRF at risk of PPHN. A review of AEs did not identify any pattern of events indicative of a safety concern with IV sildenafil. Infants will have developmental follow-up (Part B).

Trial registration Clinicaltrials.gov

NCT01720524.

Le texte complet de cet article est disponible en PDF.

Keywords : sildenafil citrate, PPHN, placebo, infant, inhaled nitric oxide, treatment failure

Abbreviations : AE, ECMO, HRF, iNO, ITT, IV, OI, PAH, PDE5, PPHN, SAE


Plan


 Study A1481316 was sponsored by Pfizer. The study sponsor (Pfizer) provided the intravenous sildenafil, financial support for the clinical research nurse and other costs of conducting the study at each site, as well as ongoing site monitoring. No honoraria or other payments were provided to the authors in relation to the manuscript. M.Z., D.I., N.C., and C.B. are full-time employees of Pfizer. R.S. serves an Associate Editor for The Journal of Pediatrics. The other authors declare no conflicts of interest.


© 2021  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 237

P. 154 - octobre 2021 Retour au numéro
Article précédent Article précédent
  • Growth Rates of Infants Randomized to Continuous Positive Airway Pressure or Intubation After Extremely Preterm Birth
  • Ariel A. Salas, Waldemar A. Carlo, Barbara T. Do, Edward F. Bell, Abhik Das, Krisa P. Van Meurs, Brenda B. Poindexter, Seetha Shankaran, Noelle Younge, Kristi L. Watterberg, Rosemary D. Higgins, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network, Alan H. Jobe, Michael S. Caplan, Abbot R. Laptook, William Oh, Betty R. Vohr, Angelita M. Hensman, Bonnie E. Stephens, Barbara Alksninis, Dawn Andrews, Kristen Angela, Susan Barnett, Bill Cashore, Melinda Caskey, Kim Francis, Dan Gingras, Regina A. Gargus, Katharine Johnson, Shabnam Lainwala, Theresa M. Leach, Martha R. Leonard, Sarah Lillie, Kalida Mehta, James R. Moore, Lucy Noel, Suzy Ventura, Rachel V. Walden, Victoria E. Watson, Michele C. Walsh, Avroy A. Fanaroff, Nancy S. Newman, Deanne E. Wilson-Costello, Bonnie S. Siner, Arlene Zadell, Julie DiFiore, Monika Bhola, Harriet G. Friedman, Gulgun Yalcinkaya, Kurt Schibler, Edward F. Donovan, Kimberly Yolton, Vivek Narendran, Kate Bridges, Barbara Alexander, Cathy Grisby, Marcia Worley Mersmann, Holly L. Mincey, Jody Hessling, Teresa L. Gratton, Ronald N. Goldberg, C. Michael Cotten, Ricki F. Goldstein, Patricia Ashley, Kathy J. Auten, Kimberley A. Fisher, Katherine A. Foy, Sharon F. Freedman, Kathryn E. Gustafson, Melody B. Lohmeyer, William F. Malcolm, David K. Wallace, Barbara J. Stoll, Susie Buchter, Anthony J. Piazza, David P. Carlton, Ira Adams-Chapman, Linda Black, Ann M. Blackwelder, Sheena Carter, Elisabeth Dinkins, Sobha Fritz, Ellen C. Hale, Amy K. Hutchinson, Maureen Mulligan LaRossa, Gloria V. Smikle, Stephanie Wilson Archer, James A. Lemons, Anna M. Dusick, Leslie D. Wilson, Faithe Hamer, Ann B. Cook, Dianne E. Herron, Carolyn Lytle, Heike M. Minnich, Mary Anne Berberich, Carol J. Blaisdell, Dorothy B. Gail, James P. Kiley, W. Kenneth Poole, Marie G. Gantz, Jamie E. Newman, Betty K. Hastings, Jeanette O'Donnell Auman, Carolyn Petrie Huitema, James W. Pickett, Dennis Wallace, Kristin M. Zaterka-Baxter, David K. Stevenson, Susan R. Hintz, M. Bethany Ball, Barbara Bentley, Elizabeth F. Bruno, Alexis S. Davis, Maria Elena DeAnda, Anne M. DeBattista, Jean G. Kohn, Melinda S. Proud, Renee P. Pyle, Nicholas H. St. John, Hali E. Weiss, Ivan D. Frantz, John M. Fiascone, Elisabeth C. McGowan, Anne Furey, Brenda L. MacKinnon, Ellen Nylen, Ana Brussa, Cecelia Sibley, Namasivayam Ambalavanan, Monica V. Collins, Shirley S. Cosby, Myriam Peralta-Carcelen, Vivien A. Phillips, Kirstin J. Bailey, Fred J. Biasini, Maria Hopkins, Kristen C. Johnston, Sara Krzywanski, Kathleen G. Nelson, Cryshelle S. Patterson, Richard V. Rector, Leslie Rodriguez, Amanda Soong, Sally Whitley, Sheree York, Neil N. Finer, Maynard R. Rasmussen, Paul R. Wozniak, Yvonne E. Vaucher, Wade Rich, Kathy Arnell, Rene Barbieri-Welge, Ayala Ben-Tall, Renee Bridge, Clarence Demetrio, Martha G. Fuller, Elaine Ito, Meghan Lukasik, Deborah Pontillo, Donna Posin, Cheryl Runyan, James Wilkes, Paul Zlotnik, John A. Widness, Jonathan M. Klein, Tarah T. Colaizy, Karen J. Johnson, Michael J. Acarregui, Diane L. Eastman, Shahnaz Duara, Charles R. Bauer, Ruth Everett-Thomas, Maria Calejo, Alexis N. Diaz, Silvia M. Frade Eguaras, Andrea Garcia, Kasey Hamlin-Smith, Michelle Harwood Berkowits, Sylvia Hiriart-Fajardo, Elaine O. Mathews, Helina Pierre, Arielle Riguard, Alexandra Stroerger, Robin K. Ohls, Janell Fuller, Julie Rohr, Conra Backstrom Lacy, Jean Lowe, Rebecca Montman, Nirupama Laroia, Dale L. Phelps, Gary J. Myers, Gary David Markowitz, Linda J. Reubens, Diane Hust, Lisa Augostino, Julie Babish Johnson, Erica Burnell, Harris Gelbard, Rosemary L. Jensen, Emily Kushner, Joan Merzbach, Jonathan Mink, Carlos Torres, David Wang, Kelley Yost, Pablo J. Sánchez, Charles R. Rosenfeld, Walid A. Salhab, Roy J. Heyne, Sally S. Adams, James Allen, Laura Grau, Alicia Guzman, Gaynelle Hensley, Elizabeth T. Heyne, Melissa H. Lepps, Linda A. Madden, Melissa Martin, Nancy A. Miller, Janet S. Morgan, Araceli Solis, Lizette E. Torres, Catherine Twell Boatman, Diana M. Vasil, Kerry Wilder, Kathleen A. Kennedy, Jon E. Tyson, Nora I. Alaniz, Patricia W. Evans, Beverly Foley Harris, Charles Green, Margarita Jiminez, Anna E. Lis, Sarah Martin, Georgia E. McDavid, Brenda H. Morris, Margaret L. Poundstone, Stacy Reddoch, Saba Siddiki, Patti L. Pierce Tate, Laura L. Whitely, Sharon L. Wright, Bradley A. Yoder, Roger G. Faix, Shawna Baker, Karie Bird, Jill Burnett, Laura Cole, Karen A. Osborne, Cynthia Spencer, Mike Steffens, Kimberlee Weaver-Lewis, Karen Zanetti, T. Michael O'Shea, Robert G. Dillard, Lisa K. Washburn, Nancy J. Peters, Barbara G. Jackson, Korinne Chiu, Deborah Evans Allred, Donald J. Goldstein, Raquel Halfond, Carroll Peterson, Ellen L. Waldrep, Cherrie D. Welch, Melissa Whalen Morris, Gail Wiley Hounshell, Athina Pappas, Beena G. Sood, Rebecca Bara, Elizabeth Billian, Laura A. Goldston, Mary Johnson, Richard A. Ehrenkranz, Vineet Bhandari, Harris C. Jacobs, Pat Cervone, Patricia Gettner, Monica Konstantino, JoAnn Poulsen, Janet Taft, Christine G. Butler, Nancy Close, Walter Gilliam, Sheila Greisman, Elaine Romano, Joanne Williams
| Article suivant Article suivant
  • Low Birth Weight as an Early-Life Risk Factor for Adult Stroke Among Men
  • Lina Lilja, Maria Bygdell, Jari Martikainen, Annika Rosengren, Claes Ohlsson, Jenny M. Kindblom

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.